These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19401427)

  • 1. Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes.
    Yang X; Zhao H; Sui Y; Ma RC; So WY; Ko GT; Kong AP; Ozaki R; Yeung CY; Xu G; Tong PC; Chan JC
    Diabetes; 2009 Jul; 58(7):1518-25. PubMed ID: 19401427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry.
    Yang X; Ma RC; So WY; Yu LW; Kong AP; Ko GT; Xu G; Ozaki R; Tong PC; Chan JC
    Cancer; 2011 Feb; 117(4):862-71. PubMed ID: 20939014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin angiotensin system inhibitors may attenuate low LDL cholesterol-related cancer risk in type 2 diabetes.
    Yang X; Ma RC; So WY; Wang Y; Kong AP; Ozaki R; Xu G; Chan JC
    Diabetes Metab Res Rev; 2014 Jul; 30(5):415-23. PubMed ID: 24677790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.
    Yang X; So WY; Ma RC; Ko GT; Kong AP; Zhao H; Luk AO; Lam CW; Ho CS; Tong PC; Chan JC
    Diabetes Care; 2009 Oct; 32(10):1826-32. PubMed ID: 19592629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
    Kong AP; Yang X; So WY; Luk A; Ma RC; Ozaki R; Cheung KK; Lee HM; Yu L; Xu G; Chow CC; Chan JC
    BMC Med; 2014 May; 12():76. PubMed ID: 24886453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin system inhibitor and statins combination therapeutics - what have we learnt?
    Koh KK; Sakuma I; Hayashi T; Kim SH; Chung WJ
    Expert Opin Pharmacother; 2015 May; 16(7):949-53. PubMed ID: 25747324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin system activation in renal adipogenesis.
    Sui Y; Zhao HL; Fan RR; Guan J; He L; Lee HM; Chan JC; Tong PC
    Am J Physiol Renal Physiol; 2010 Feb; 298(2):F391-400. PubMed ID: 19940035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist.
    Haddad GE; Blackwell K; Bikhazi A
    Can J Physiol Pharmacol; 2003 Feb; 81(2):142-9. PubMed ID: 12710528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Kong AP; Lee HM; Xu G; Ozaki R; Chan JC
    Acta Diabetol; 2012 Dec; 49 Suppl 1():S185-93. PubMed ID: 22722949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrarenal renin-angiotensin system contributes to tubular acidification adaptation following uninephrectomy.
    Amorena C; Damasco C; Igarreta P; MacLaughlin M
    Exp Nephrol; 2001; 9(1):60-4. PubMed ID: 11053982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of renin-angiotensin system and adenosine monophosphate-activated protein kinase signaling pathway in renal carcinogenesis of uninephrectomized rats.
    Yang KK; Sui Y; Zhou HR; Zhao HL
    Tumour Biol; 2017 May; 39(5):1010428317699116. PubMed ID: 28459365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes.
    Yang X; Ma RC; So WY; Ko GT; Kong AP; Zhao H; Xu G; Tong PC; Chan JC
    Diabetes Res Clin Pract; 2010 Jan; 87(1):117-25. PubMed ID: 19932519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Kong AP; Lee HM; Yu LW; Chow CC; Ozaki R; Ko GT; Chan JC
    Diabetes Care; 2011 Feb; 34(2):375-80. PubMed ID: 20980414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.